Octreotide-induced bradycardia

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 413-416

  Herrington, Annie M ^a,b   George, Kevin W ^a   Moulds, Christine C ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; RINGER LACTATE SOLUTION; SOMATOSTATIN;

ADULT; ARTICLE; BRADYCARDIA; CASE REPORT; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANEMIA, HEMOLYTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BRADYCARDIA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; OCTREOTIDE;

EID: 0031919290     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Sandoz Pharmaceuticals. Sandostatin product information. East Hanover, NJ; 1996.
2. Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989;8(4):255-73.
3. ®)-induced bradycardia: a case report. Hospital Pharmacy 1997;32(10):1359-61.
4. McCormick PA, Chin J, Greenslade L, et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995;21(5):1255-60.
5. Naeije R, Hallemans R, Mols P, Melot C, Reding P. Effects of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis. Crit Care Med 1982;10(9):578-81.
6. Gaudin C, Moreau R, Champigneulle B, Soubrane O, Kleber G, Lebrec D. Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995;15:236-41.
7. Hsia HC, Lin HC, Lee FY, et al. Changes of hepatic and systemic haemodynamics following somatostatin administration in patients with hepatitis B-related cirrhosis. J Gastroenterol Hepatol 1993;8:15-20.
8. Soderman C, Juhlin-Dannfelt A, Lagerstrand L, Eriksson LS. Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol 1994;21(1):52-7.
9. Zironi G, Rossi C, Siringo S, et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study. Liver 1996;16: 225-34.
10. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981;80:518-25.
11. Eriksson LS, Brundin T, Soderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919-25.